Innovative GLP-1 Oral Medication Promises Significant Weight Loss
Eli Lilly's new oral GLP-1 medication, orforglipron, shows promise in significant weight loss and improved blood sugar control in clinical trials, offering a convenient alternative to injections for obesity treatment.
A groundbreaking development in weight management has emerged with Eli Lilly's new oral GLP-1 receptor agonist, orforglipron. In a recent late-stage clinical trial, participants with overweight, obesity, and type 2 diabetes experienced remarkable weight loss and improved blood sugar levels after using this once-daily pill.
Participants who received the highest dose of 36 milligrams lost an average of nearly 23 pounds (about 10.5% of their body weight) over a 72-week period. Additionally, the medication reduced their A1C levels—a key marker of blood sugar control—by approximately 1.8%. These results are promising, suggesting the pill's potential to effectively treat obesity and related metabolic conditions.
Compared to existing oral GLP-1 options such as Rybelsus, orforglipron offers the advantage of not requiring strict fasting or water restrictions, making it a more convenient option for many. Its development aims to provide an alternative to injectable treatments, which can be challenging for some patients.
The reported side effects were generally mild to moderate, with gastrointestinal discomfort, such as upset stomach, being the most common. If regulatory approval is granted, orforglipron could become an accessible and user-friendly treatment for millions struggling with obesity and type 2 diabetes.
Eli Lilly is also exploring additional uses for the medication, including potential benefits for high blood pressure and sleep apnea. With production already underway to meet anticipated demand, the company's chief scientific officer, Dr. Dan Skovronsky, highlighted the readiness to distribute the medication widely.
The trial findings, although not yet peer-reviewed, mark a significant step forward in oral obesity treatments and metabolic health management.
Source: https://medicalxpress.com/news/2025-08-glp-pill-people-pounds.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
FDA Incorporates AI Technology to Accelerate Drug and Food Safety Assessments
The FDA is leveraging artificial intelligence, including a new tool called Elsa, to accelerate drug and food safety review processes and improve public health outcomes.
Advances and Challenges in Alzheimer's Disease Research: A Vital Turning Point
Recent advancements in Alzheimer's disease research offer hope for early detection and new treatments, but funding and translational challenges remain critical hurdles. Experts emphasize the importance of multidisciplinary approaches to slow or prevent disease progression.
Improved Survival in Liver Cancer Patients Using Dual Immunotherapy
A novel dual immunotherapy approach combining nivolumab and ipilimumab has significantly improved survival rates and tumor control in patients with advanced liver cancer, offering new hope for treatment. The success of recent clinical trials has led to global approval, marking a major breakthrough in liver cancer management.